Annotator® - "Tumor Identity Cards (CIT)®" Database

Head :
Ayadi Mira, CIT / Recherche
De Reyniès Aurélien , CIT / Recherche
Petel Fabien, CIT / Recherche

Last update : 12/08/2015 | Version : 2 | ID : 8214

print
Print
xml
XML

Export to XML

Please choose the format :

pdf
PDF
xml
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

Which version do you want to export ?

send
Send
General
Identification
Detailed name "Tumor Identity Cards (CIT)®" Database
Sign or acronym Annotator®
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL approval - no. 1381614
General Aspects
Medical area Biology
Cancer research
Immunology
Health determinants Addictions
Genetic
Geography
Lifestyle and behavior
Medicine
Occupation
Keywords genome, methylation patterns, French National League Against Cancer, alterations, chromosomal rearrangement, gene expression, microRNA, cancer cells, personalised medicine, exons
Scientific investigator(s) (Contact)
Name of the director Ayadi
Surname Mira
Address 14 rue Corvisart
Phone 01 53 55 24 00
Email Mira.Ayadi@ligue-cancer.net
Unit CIT / Recherche
Organization Ligue Nationale Contre le Cancer
Name of the director De Reyniès
Surname Aurélien
Phone 01 53 55 24 00
Unit CIT / Recherche
Organization Ligue Nationale Contre le Cancer
Name of the director Petel
Surname Fabien
Address 14 rue Corvisart, 75013 Paris, France
Phone 01 53 55 24 00
Email Fabien.Petel@ligue-cancer.net
Unit CIT / Recherche
Organization Ligue Nationale Contre le Cancer
Collaborations
Participation in projects, networks and consortia Yes
Details More than 80 projects have been performed as part of the CIT programme over 20 different cancer types; more than 100 publications in international journals.
Others The CIT Programme has created a national network of clinicians, researchers and institutions
Funding
Funding status Private
Details CIT is a national cancer genomics programme that is established, funded and managed by the French National League Against Cancer since 2000.
Governance of the database
Sponsor(s) or organisation(s) responsible Ligue Nationale contre le Cancer (French League against Cancer)
Organisation status Private
Presence of scientific or steering committees Yes
Additional contact
Main features
Type of database
Type of database Study databases
Study databases (details) Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary A selection of health institutions and services
Database recruitment is is made on the basis of: Medication(s) taken
Another treatment or procedure
Database recruitment is carried out as part of an interventional study No
Additional information regarding sample selection. The CIT programme relies on a national network of researchers and clinicians, and on a set of technological platforms (molecular biology 'omics').
Database objective
Main objective To comprehensively characterise and integrate cellular signals and associate them with patient history and treatments. Biological events can be genome alterations, mutations, chromosomal rearrangements, gene and miRNA expressions, methylation patterns, exon variations, etc.. As such, CIT is developing an integrated view of how cancer cells develop and function. This work forms the basis of personalised medicine that is adapted to the genomic characteristics of each tumour. CIT may then identify molecular signatures of patients who are more likely to respond well to a treatment, or whose cancer is deemed more aggressive, therefore helping MDs to choose the best treatment and care.
Inclusion criteria Inclusion criteria depends on each cancer-specific project inside the CIT Programme, and relate to the biological and clinical questions raised by the PIs. Studies may involve patient monitoring within a hospital setting, or patients previously included in a prospective clinical study. Informed patient consent is obtained beforehand. Studied diseases may be paediatric tumours or adult cancers, and may apply to solid tumours or hematologic malignancies or lymphoma. Secure data access is restricted to the researchers involved in the Programme.
Population type
Age Newborns (birth to 28 days)
Infant (28 days to 2 years)
Early childhood (2 to 5 years)
Childhood (6 to 13 years)
Adolescence (13 to 18 years)
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)
Population covered Sick population
Gender Male
Woman
Geography area National
Detail of the geography area France mainly; some european cohorts
Data collection
Dates
Date of first collection (YYYY or MM/YYYY) 2000
Date of last collection (YYYY or MM/YYYY) 2015
Size of the database
Size of the database (number of individuals) [10 000-20 000[ individuals
Details of the number of individuals Mid-2015, the CIT programme's database was containing histological, clinical and biological information from 13,000 anonymized patients, all types of cancer included, and 19,000 'omics' experiments (SNP/Expression/miRNA/Exon/Methylation; microarray or NGS).
Data
Database activity Current data collection
Type of data collected Clinical data
Paraclinical data
Biological data
Clinical data (detail) Direct physical measures
Details of collected clinical data diagnosis, stage, grade, pathological conditions, side-effects
Paraclinical data (detail) Protein expression; gene mutation identification (ABCB1, AKT1, APC, BCL2, BRAF, BRCA1 / 2, CCND1, CDKN2A, CTNNB1, EGFR, ERBB2, etc.), known translocations (1p/19q) or alterations (microsatellite allelic loss, etc.).
Biological data (detail) Presence of adenomas. Cellular morphology, differentiation, fibrosis, mitosis and necrosis. Percentage of tumour cells. Hyperplasia. AFP. Albumin. ALP. B2 microglobulin. Bilirubin. CEA. LDH. Metanephrine. PSA. Sedimentation rate. WBC.
Presence of a biobank Yes
Contents of biobank Whole blood
Blood cells isolated
Tissues
Cell lines
DNA
DNAc/RNAm
Others
Details of biobank content Tumour samples.
Health parameters studied Health event/morbidity
Health event/mortality
Others
Other (detail) relapse, metastasis, second cancer
Procedures
Classifications used ICD
Quality procedure(s) used external ontologies and internal semi-structured vocabulary
Participant monitoring Yes
Links to administrative sources No
Promotion and access
Promotion
Link to the document http://cit.ligue-cancer.net/?page_id=59
Description List of publications
Access
Presence of document that lists variables and coding procedures Yes
Terms of data access (charter for data provision, format of data, availability delay) Secure data access is restricted to the researchers involved in the CIT Programme
Access to aggregated data Access on specific project only
Access to individual data Access on specific project only

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here